Abstract. Background/Aim: Vintage hormone therapy for non-metastatic castration-resistant prostate cancer (nmCRPC) is not recommended under the current guidelines, but is widely practiced in Japan. This study assessed effectiveness of vintage hormone therapy as alternative androgen deprivation therapy (AADT) for treatment of nmCRPC. Patients and Methods: In this retrospective study we examined patients with nmCRPC that received vintage hormone therapy as AADT between 1999 and 2018. Results: Of 53 patients with nmCRPC, 25 patients (47.2%) had stage 1 nodal disease (N1) at diagnosis of nmCRPC. Prostate specific antigen (PSA) reduction rate≥30% was observed in 32 patients (72.7%). The median PSA nadir was 0.7, and the duration of the response was 14.3 months. The median metastasis-free survival (MFS) for the entire patient population was 62.2 months, and the median overall survival (OS) was not reached. In the multivariate analysis, the duration of response in AADT>18 months was a predictor of prolonged OS. Conclusion: There is a certain number of nmCRPC patients who respond well to vintage hormone therapy as AADT. Further studies are expected to differentiate such cases.

Prostate cancer (PC) is the most common cancer in men, and it is a leading cause of cancer-related deaths in developed countries (1, 2). The development and widespread use of prostate-specific antigen (PSA) screening tests has contributed to the detection of early PC, reducing mortality from it (3, 4). Androgen deprivation therapy (ADT) is the mainstay of treatment for patients with advanced and locally-advanced PC. It is also one of the main treatment options following biochemical recurrence in patients with localized PC who have undergone local treatment, such as surgery or radiation (5). Most patients with PC initially show a favorable response to ADT. Nevertheless, failure of ADT is nearly unavoidable, and most PC progresses to castration-resistant PC (CRPC). Non-metastatic CRPC (nmCRPC) has no obvious metastases other than local lymph node metastasis, as determined by conventional imaging, and is clinically differentiated from metastatic CRPC (mCRPC) in therapeutic strategies. Patients with mCRPC, especially those with visceral metastases, have been found to have very poor prognosis (6, 7). Delaying the progression to mCRPC by treating for nmCRPC may be key to improving the prognosis of patients with PC. According to 2020 National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Prostate Cancer, it is now a category 1 recommendation to use apalutamide, darolutamide, and enzalutamide for the treatment of nmCRPC (8). However, second-line (vintage) hormone therapy is still widely used as an alternative antiandrogen therapy (AADT) in Japan for men with nmCRPC (9). In this study, we retrospectively investigated the effect of vintage hormone therapy as AADT in patients with nmCRPC. Additionally, we examined prognostic factors.

Patients and Methods

Study design. In this study, 53 patients with nmCRPC that received vintage hormone therapy as AADT after failure of primary ADT at Kanazawa University Hospital between 1999 and 2018 were
included. All patients were histologically diagnosed with adenocarcinoma of the prostate, initially treated with combined androgen blockade, and showed disease progression following initial treatment. PSA failure after ADT was defined as a PSA level at least 2.0 ng/ml higher and a 25% rise from the nadir level, which was confirmed by a second PSA test at least 4 weeks later. Cases satisfying the above criteria were diagnosed as CRPC.

Vintage hormonal agents included: i) bicalutamide, ii) flutamide, iii) chlormadinone, iv) estramustine, and v) ethinylestradiol. We retrospectively reviewed the charts of all the patients and analyzed the relevant data. The collected medical data included: i) age, ii) serum PSA level, iii) prostate biopsy pathology, iv) clinical stage, and v) treatment progress. The clinical stage was determined based on the 2017 TNM Classification of Malignant Tumors, 8th Edition (10). Cancer staging used: i) computerized tomography (CT), ii) magnetic resonance imaging (MRI), and iii) bone scintigraphy. Imaging tests, such as CT and MRI, were performed at the time of PC diagnosis and at the progression to CRPC. After that, the interval between subsequent imaging studies and all therapeutic decisions were at the discretion of each attending physician. Follow up was terminated on May 31, 2020. Survival was measured from the time of diagnosis of nmCRPC until death or the last follow up.

Statistical analysis. Metastasis-free survival (MFS) and overall survival (OS) were retrospectively analyzed using the Kaplan-Meier method. The Cox proportional hazard model was used for multivariate analyses. Log-rank tests were used for the comparison of the survival distributions. Statistical analyses were performed using SPSS software, version 25.0 (SPSS Inc., Chicago, IL, USA) and Prism 5 (GraphPad, San Diego, CA, USA). In all analyses, a p-value of less than 0.05 indicated statistical significance. This study was approved by the institutional review board of Kanazawa University Hospital (2016-328).

Results

Patient characteristics for primary ADT. Patient characteristics for primary ADT are shown in Table I. The median age at PC diagnosis for the 53 patients who met the

Table I. Patient characteristics in primary ADT.

| Vintage hormone therapy | n | Median age at diagnosis of PC, yr (range) 72 (55-86) | Median PSA at diagnosis of PC, ng/ml (range) 68.4 (5.6-841.5) |
|-------------------------|---|---------------------------------------------|--------------------------------------------------|
| Histology               |   |                                             |                                                  |
| GS≤6                    | 1 |                                             |                                                  |
| GS=7                    | 13|                                             |                                                  |
| GS≥8                    | 35|                                             |                                                  |
| Unknown                 | 4 |                                             |                                                  |
| T stage at diagnosis of PC |   | ≤T2 14                                       | ≥T3 28                                           |
| N stage at diagnosis of PC |   | N0 27                                        | N1 22                                           | Nx 4                                            |
| Primary localized treatment |   | CAB only 28                                  | Radiation 20                                     | Radical prostatectomy 5                          |
| Castration              |   | Leuprolerin 43                               | Goserelin 6                                      | Degarelix 4                                     |
| Antiandrogen (1st)      |   | Bicalutamide 41                              | Chlormadinone 10                                | Estramustine 1                                  |
| PSA reduction rate (%)  |   | ≥30% 32                                       | <30% 12                                         | ≥50% 25                                         |
| Antiandrogen (2nd)      |   | Flutamide 32                                  | Bicalutamide 11                                  | Chlormadinone 3                                 |
| PSA reduction rate (%)  |   | ≥30% 32                                       | <30% 12                                         | ≥50% 25                                         |
| Antiandrogen (3rd)      |   | ARST (3rd) 9                                 | PSA reduction rate ≥50% 7                       |

ADT: Androgen-deprivation therapy; PC: prostate cancer; PSA: prostate-specific antigen; GS: Gleason score; CAB: combined androgen blockade; ARST: androgen receptor signaling-targeted agent.

Table II. Patient characteristics in AADT.

| Vintage hormone therapy | n | Median age at diagnosis of CRPC, yr (range) 76 (58-90) | Median PSA nadir value during ADT, ng/ml (range) 0.7 (0.008-13.198) |
|-------------------------|---|---------------------------------------------|--------------------------------------------------|
| N stage at diagnosis of CRPC |   | N0 27                                       | N1 25                                           | Nx 1                                            |
| Antiandrogen withdrawal syndrome, n (%) |   | 22 (41.5%)                                 | Anti-androgen withdrawal response, n (%) 8 (36.4%) |
| Antiandrogen (2nd)      |   | Flutamide 32                                  | Bicalutamide 11                                  | Chlormadinone 3                                 |
| PSA reduction rate (%)  |   | ≥30% 32                                       | <30% 12                                         | ≥50% 25                                         |
| Antiandrogen (3rd)      |   | ARST (3rd) 9                                 | PSA reduction rate ≥50% 7                       |

AADT: Alternative androgen-deprivation therapy; CRPC: castration-resistant prostate cancer; PSA: prostate-specific antigen; ARST: androgen receptor signaling-targeted agent.
inclusion criteria was 72 years (range=55-86 years). Twenty-eight patients started treatment with combined androgen blockade (CAB) alone, and 25 patients received some form of curative treatment. The most commonly administered primary anti-androgen was bicalutamide (41 patients), followed by chlormadinone (10 patients). The median PSA nadir was 0.13 ng/ml, and the duration of response was 24.4 months.

The patient characteristics for AADT. The patient characteristics for AADT are shown in Table II. The median age at diagnosis of nmCRPC was 76 years (range: 58-90). Twenty-five patients (47.2%) had stage 1 nodal disease (N1) at diagnosis of nmCRPC. PSA reduction rate≥30% was observed in 32 patients (72.7%). PSA reduction rate≥50% was observed in 25 patients (56.8%). The median PSA nadir was 0.7 ng/ml, and duration of response was 14.3 months.

Table III. Univariate and multivariate analyses on MFS and OS from diagnosis of nmCRPC.

|                          | MFS from diagnosis of nmCRPC | OS from diagnosis of nmCRPC |
|--------------------------|-----------------------------|-----------------------------|
|                          | Univariate | Multivariate | Univariate | Multivariate |
|                          | HR (95% CI) | p-Value | HR (95% CI) | p-Value | HR (95% CI) | p-Value | HR (95% CI) | p-Value |
| T stage at diagnosis of PC | 1.03 (0.44-2.44) | 0.94 | 1.66 (0.46-6.05) | 0.44 |
| (≤T2 vs. ≥T3)            |             |       |             |       |
| N stage at diagnosis of PC | 0.98 (0.44-2.16) | 0.96 | 0.99 (0.34-2.86) | 0.99 |
| (N0 vs. N1)              |             |       |             |       |
| Gleason score (≤8 vs. ≥9) | 1.93 (0.85-4.38) | 0.12 | 1.37 (0.37-5.04) | 0.63 |
| AWS (Yes vs. No)         | 1.04 (0.35-3.08) | 0.94 | 1.42 (0.26-7.78) | 0.69 |
| PSA nadir in primary ADT  | 1.12 (0.43-2.91) | 0.81 | 0.90 (0.19-4.36) | 0.9 |
| (<0.3 vs. ≥0.3)          |             |       |             |       |
| Duration of response in primary ADT (≥18 vs. <18 months) | 1.07 (0.48-2.39) | 0.87 | 1.17 (0.38-3.58) | 0.79 |
| Age at diagnosis of nmCRPC | 0.70 (0.32-1.53) | 0.36 | 0.45 (0.16-1.24) | 0.12 |
| (<70 vs. ≥70 yr)         |             |       |             |       |
| T stage at diagnosis of CRPC | 1.00 (0.38-2.62) | 1 | 1.26 (0.34-4.67) | 0.73 |
| (≤T2 vs. ≥T3)            |             |       |             |       |
| N stage at diagnosis of CRPC | 1.26 (0.59-2.71) | 0.55 | 1.51 (0.52-4.39) | 0.45 |
| (N0 vs. N1)              |             |       |             |       |
| NLR at diagnosis of nmCRPC | 0.38 (0.07-2.01) | 0.26 | 1.32 (0.18-9.43) | 0.79 |
| (<3 vs. ≥3)              |             |       |             |       |
| PLR at diagnosis of nmCRPC | 0.73 (0.15-3.65) | 0.7 | 0.73 (0.1-5.46) | 0.76 |
| (<160 vs. ≥160 mg/dl)    |             |       |             |       |
| LDH at diagnosis of nmCRPC | 0.94 (0.37-2.55) | 0.94 | 0.99 (0.27-3.69) | 0.99 |
| (<200 vs. ≥200 IU/l)     |             |       |             |       |
| PSA at diagnosis of nmCRPC | 1.35 (0.60-3.03) | 0.46 | 1.19 (0.35-4.09) | 0.78 |
| (≤3 vs. >3 ng/ml)        |             |       |             |       |
| Duration of response in alternative ADT (≥18 vs. <18 months) | 3.12 (1.38-7.07) | 0.006 | 6.07 (1.20-30.63) | 0.03 |
| PSA response rate in alternative ADT (≥30 vs. <30%) | 4.72 (1.37-16.24) | 0.014 | 3.06 (0.85-11.02) | 0.09 |

MFS: Metastasis-free survival; OS: overall survival; nmCRPC: non-metastatic castration-resistant prostate cancer; PC: prostate cancer; AWS: anti-androgen withdrawal syndrome; ADT: androgen-deprivation therapy; NLR: neutrophil-to-lymphocyte ratio; CRP: C-reactive protein; LDH: lactate dehydrogenase; PSA: prostate-specific antigen.

Univariate and multivariate analyses on MFS and OS from diagnosis of nmCRPC. Table III shows the results of univariate and multivariate analyses on MFS and OS from the diagnosis of nmCRPC. Multivariate analysis showed that the duration of response in AADT less than 18 months (m) was a predictor of prolonged OS.

MFS and OS from the diagnosis of nmCRPC. Figure 1A and B shows MFS and OS from the diagnosis of nmCRPC, respectively. The median MFS for the entire patient population was 62.2 months, and the median OS was not reached. The median MFS for the duration response in AADT>18 m group was 93.0 months, and for the duration response in AADT≤18 m group was 33.5 months (p=0.009). The median OS in the duration response in AADT>18 m group was not reached, while the median OS in the duration response in AADT≤18 m group was 75.1 months (p=0.01).
Survival was significantly prolonged in the duration response in AADT>18 m group.

Discussion

Prognosis for patients with mCRPC is generally poor, reported to be about 17-35 months (7, 11-14). The most important goal in the treatment of nmCRPC is to delay the progression to mCRPC. In fact, it has been reported that there is a significant correlation between MFS and OS (15). Phase III PROSPER, SPARTAN, and ARAMIS trials in patients with nmCRPC have shown that enzalutamide, apalatinamide, or dalrotamide can significantly prolong MFS compared to placebo (16-18). The median MFS in the above ARST group was 36.6-40.5 months, and the median MFS in the placebo group was 14.7-18.4 months. In Japan, vintage hormone therapy for patients with nmCRPC is still widely used as an AADT, but it is unclear whether it has the same effect as androgen receptor-signaling targeted agents (ARST) (9). If the PSA response is defined as a decrease in PSA of 50% or more, previous reports have shown that a PSA response was observed in 30.8% to 46% of CRPC patients who received vintage hormone therapy as AADT (19-26). In a study comparing vintage hormone therapy with ARST as an AADT, a report has described ARST or vintage hormone therapy to 103 patients with nmCRPC. The PSA response rate was 36.2% in the vintage hormone group and 62.5% in the ARST group (26). In a study comparing vintage hormone therapy to ARST as an AADT for 396 patients with CRPC, including 139 patients with nmCRPC, the PSA response rate was 31% in the bicalutamide group and 81% in the enzalutamide group (p<0.001) (22). Even when limited to 139 patients with nmCRPC, the PSA response rate was 42% in the flutamide group and 91% in the enzalutamide group, which was like the results for all patients with CRPC (p<0.001). In another report of 55 patients with CRPC treated with enzalutamide or flutamide, including those with nmCRPC, the PSA response rate was 30.8% in the flutamide group and 86.2% in the enzalutamide group (p<0.01) (23). In the present study, the PSA response rate was 56.8%, which was slightly lower compared to the rate of ARST-treated patients from previous reports. These results suggest that ARST may be more favorable for PSA reduction compared to the vintage hormone therapy. In an earlier study, the PSA response rate was similar for those who received enzalutamide as an AADT and those who received flutamide followed by enzalutamide as a 2nd line treatment (86.2% and 77.8%, respectively, p=0.69) (23). In this study, the PSA response rate in the group receiving flutamide followed by ARST as a second line treatment was 77.8%, which was a good result (Table II). From these results, it is possible that ARST for nmCRPC will result in a comparable PSA reduction with both 1st and 2nd line treatments. PSA decline is important, but it does not perfectly correlate with survival. In the two aforementioned studies, there was no significant difference in OS between the vintage and ARST groups (23, 26). In this study, the median OS was not reached even though the median observation period was as long as 48.5 months, which was a good result compared to the past ARST-administered group (23, 26). From previous reports, no significant difference in OS was observed between the vintage and ARST groups, suggesting that there must be a certain number of cases in which vintage hormone therapy can be effective as an AADT. It would be valuable, from a medical economic point of view, to
distinguish between cases in which vintage hormone therapy is effective as an AADT for nmCRPC. In the multivariate analysis we examined the factors that prolong MPS and OS from the diagnosis of nmCRPC, and found that the duration response in AADT>18 m was a predictor of prognosis. If vintage hormone therapy can highlight the cases in which the duration response in AADT>18 m can be expected, it may be possible to effectively use vintage hormones while retaining ARST as an option. Larger prospective studies are required in the future to identify cases in which vintage hormone therapy may be beneficial. Cases with a PSA nadir value in primary ADT>1 ng/ml and a time to PSA nadir during primary ADT>1 year have been reported to be less effective when vintage hormone therapy is administered as AADT, which may assist in case selection (27). Additional useful information for case selection could be: i) a PSA decrease of less than 97% after 3 months of vintage hormone therapy for metastatic hormone-sensitive prostate cancer (mHSPC) as a predictor of poor prognosis, and ii) vintage hormone therapy for patients with nmCRPC with short PSA doubling time (PSADT) also associated with poor prognosis (28, 29).

There are several limitations in the current study. It is a retrospective comparative study with a short observation period involving a small number of patients, all of whom are Japanese. Furthermore, PC treatment and the interval between imaging assessment are at the discretion of the attending physician.

In conclusion, there are a certain number of patients who respond well to vintage hormone therapy as AADT for nmCRPC. It is hoped that further studies will be able to distinguish such cases.

Conflicts of Interest

All Authors declare that there are no potential conflicts of interest relevant to this article.

Authors’ Contributions

HI designed the experiments. HI, HK, TS, RN, TM, SK, HY, SK, KI, and YK collected clinical data. HI, RN, TM, SK, KI and AM analyzed the data. HI, KI, and AM drafted and revised the manuscript. All authors read and approved the final version of the manuscript.

References

1. Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin 69(1): 7-34, 2019. PMID: 30620402. DOI: 10.3322/caac.21551
2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin 65(2): 87-108, 2015. PMID: 25651787. DOI: 10.3322/caac.21262
3. Byers T, Barrera E, Fontham ET, Newman LA, Runowicz CD, Sener SF, Thun MJ, Winborn S and Wender RC: A midpoint assessment of the american cancer society challenge goal to halve the u.S. Cancer mortality rates between the years 1990 and 2015. Cancer 107(2): 396-405, 2006. PMID: 16770789. DOI: 10.1002/cncr.21990
4. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwantkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recke F, Paev A, Maattanen L, Bangma CH, Aus G, Carlsson S, Villers A, Reillard X, van der Kwast T, Kujala PM, Blijenberg BG, Stenman UH, Huber A, Taari K, Hakama M, Moss SM, de Koning HJ and Auvinen A: Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 366(11): 981-990, 2012. PMID: 22417251. DOI: 10.1056/NEJMoa1113135
5. Sharifi N, Gulley JL and Dahut WL: An update on androgen deprivation therapy for prostate cancer. Endocr Relat Cancer 17(4): R305-315, 2010. PMID: 20861285. DOI: 10.1677/ERC-10-0187
6. Halabi S, Kelly WK, Ma H, Zhou H, Solomon NC, Fizazi K, Tangen CM, Rosenthal M, Petrylak DP, Hussain M, Vogelzang NJ, Thompson IM, Chi KN, de Bono J, Armstrong AJ, Eisenberger MA, Fandi A, Li S, Araujo JC, Logothetis CJ, Quinn DI, Morris MJ, Higano CS, Tannock IF and Small EJ: Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer. J Clin Oncol 34(14): 1652-1659, 2016. PMID: 26951312. DOI: 10.1200/JCO.2015.65.7270
7. Iwamoto H, Izumi K, Shimada T, Kano H, Kadomo S, Makino T, Naito R, Yaegashi H, Shigehara K, Kadomo Y and Mizokami A: Androgen receptor signaling-targeted therapy and taxane chemotherapy induce visceral metastasis in castration-resistant prostate cancer. Prostate, 2020. PMID: 33047850. DOI: 10.1002/ pros.24082
8. Network® NCC: Nccn clinical practice guidelines in prostate cancer. Version 2, 2020. Available at: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf [Last accessed on January 21 2021]
9. Mizokami A, Kadono Y, Kitagawa Y, Izumi K and Konaka H: Therapies for castration-resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines. Int J Urol 24(8): 566-572, 2017. PMID: 28577511. DOI: 10.1111/iju.13372
10. Brierley JD, Gospodarowicz MK and Wittekind C: TNM classification of malignant tumours, 8th edition. John Wiley & Sons, Ltd, 2017.
11. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noorberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B and Investigators P: Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371(5): 424-433, 2014. PMID: 24881730. DOI: 10.1056/NEJMoa1405095
12. Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jr., Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D and Crawford ED: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351(15): 1513-1520, 2004. PMID: 15470214. DOI: 10.1056/NEJ Moa041318
13. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PFA, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaq TW, Taplin M-E, Higano CS, de Souza P, de Bono JS,
14 Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Smith MR, Saad F, Chowdhury S, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA and Eisenberger MA: Docetaxel plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (cou-aa-302): Final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. The Lancet Oncology 16(2): 152-160, 2015. PMID: 25601341. DOI: 10.1016/S1470-2045(14)71205-7

15 Mori A, Hashimoto K, Koroki Y, Wu DB and Masumori N: The correlation between metastasis-free survival and overall survival in non-metastatic castration resistant prostate cancer patients from the medical data vision claims database in Japan. Curr Med Res Opin 35(10): 1745-1750, 2019. PMID: 31084438. DOI: 10.1080/03007995.2019.1619543

16 Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, Ivashchenko P, Demirhan E, Modelska K, Phung, Krivoshik A and Sternberg CN: Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med 378(26): 2465-2474, 2018. PMID: 29949494. DOI: 10.1056/NEJMoa1800720

17 Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Giltz A, Trudel GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu MK, Small EJ and Investigators S: Apalutamide treatment in men with non-metastatic castration-resistant prostate cancer after initial maximum androgen blockade. J Urol 190(1): 124-132, 2018. PMID: 29420164. DOI: 10.1016/j.juro.2019.05.002

18 Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Kappeler C, Snapir A, Sarapohja T and Smith MR: Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 380(13): 1235-1246, 2019. PMID: 30763142. DOI: 10.1056/NEJMoa1815671

19 Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, Fujii M, Takihana Y, Usui T, Matsuda T, Ozono S, Kumon H, Ichikawa T and Miki T: Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol 180(3): 921-927, 2008. PMID: 18635218. DOI: 10.1016/j.juro.2008.05.045

20 Okegawa T, Ntaharaka K and Hagishihara E: Alternative antiandrogen therapy in patients with castration-resistant prostate cancer: A single-center experience. Int J Urol 17(11): 950-955, 2010. PMID: 20807265. DOI: 10.1111/j.1442-2042.2010.02620.x

21 Takada T, Ishizuya Y, Okada T, Ueda T, Inoue H and Hara T: Alternative antiandrogen therapy with flutamide in patients with castration-resistant prostate cancer: A single center experience. Hinyokika Kiyo 57(6): 291-295, 2011. PMID: 21795830.

22 Penson DF, Armstrong AJ, Concepcion R, Agarwal N, Olsson C, Karsh L, Dunsecce C, Wang W, Wu K, Krivoshik A, Phung D and Higano CS: Enzalutamide versus bicalutamide in castration-resistant prostate cancer. The stride trial. J Clin Oncol 34(18): 2098-2106, 2016. PMID: 26811535. DOI: 10.1200/JCO.2015.64.9285

23 Iguchi T, Tamada S, Kato M, Yasuda S, Otoshi T, Hamada K, Yamasaki T and Nakatani T: Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: A retrospective study. Int J Clin Oncol, 2019. PMID: 30741370. DOI: 10.1007/s10147-019-01413-1

24 Nakano T, Kadono Y, Iwamoto H, Yaegashi H, Iijima M, Kawaguchi S, Nohara T, Shigehara K, Izumi K and Mizokami A: Therapeutic effect of ethinylestradiol in castration-resistant prostate cancer. Anticancer Res 40(4): 2291-2296, 2020. PMID: 32234928. DOI: 10.21873/anticancer.14194

25 Izumi K, Kadono Y, Shima T, Konaka H, Mizokami A, Koh E and Namiki M: Ethinylestradiol improves prostate-specific antigen levels in pretreated castration-resistant prostate cancer patients. Anticancer Res 30(12): 5201-5205, 2010. PMID: 21187513.

26 Miyake H, Matsushita Y, Watanabe H, Tamura K, Motoyama D, Ito T, Sugiyama T and Otsuka A: Comparative assessment of prognostic outcomes between first-generation antiandrogens and novel androgen-receptor-axis-targeted agents in patients with non-metastatic castration-resistant prostate cancer. Int J Clin Oncol 24(7): 842-847, 2019. PMID: 30739263. DOI: 10.1007/s10147-019-01412-2

27 Fukuo K, Teishima J, Nagamatsu H, Inoue S, Hayashi T, Mita K, Shigeta M, Kobayashi K, Kajiwara M, Kadonishi Y, Tacho T and Matsubara A: Predictors of poor response to first-generation antiandrogens as criteria for alternate treatments for patients with non-metastatic castration-resistant prostate cancer. Cancer Res 80(13): 3563-3570, 2020. PMID: 32162272. DOI: 10.1158/0008-5472.CAN-19-2953

28 Miyake H, Watanabe K, Matsushita Y, Watanabe H, Tamura K, Motoyama D, Ito T, Sugiyama T and Otsuka A: Assessment of factors predicting disease progression in Japanese patients with non-metastatic castration-resistant prostate cancer. Int J Clin Oncol 24(7): 842-847, 2019. PMID: 30739263. DOI: 10.1007/s10147-019-01412-2

29 Miyake H, Watanabe K, Matsushita Y, Watanabe H, Tamura K, Motoyama D, Ito T, Sugiyama T and Otsuka A: Assessment of factors predicting disease progression in Japanese patients with non-metastatic castration-resistant prostate cancer. Anticancer Res 40(2): 1101-1106, 2020. PMID: 32014960. DOI: 10.21873/anticancer.14049

30 Miyazawa T, Iguchi T, Tamada S, Iguchi T, Tamada S, Kato M, Yasuda S, Otoshi T, Hamada K, Yamasaki T and Nakatani T: Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: A retrospective study. Int J Clin Oncol, 2019. PMID: 30741370. DOI: 10.1007/s10147-019-01413-1

31 Nakano T, Kadono Y, Iwamoto H, Yaegashi H, Iijima M, Kawaguchi S, Nohara T, Shigehara K, Izumi K and Mizokami A: Therapeutic effect of ethinylestradiol in castration-resistant prostate cancer. Anticancer Res 40(4): 2291-2296, 2020. PMID: 32234928. DOI: 10.21873/anticancer.14194

32 Penson DF, Armstrong AJ, Concepcion R, Agarwal N, Olsson C, Karsh L, Dunsecce C, Wang W, Wu K, Krivoshik A, Phung D and Higano CS: Enzalutamide versus bicalutamide in castration-resistant prostate cancer. The stride trial. J Clin Oncol 34(18): 2098-2106, 2016. PMID: 26811535. DOI: 10.1200/JCO.2015.64.9285

Received January 6, 2021
Revised January 20, 2021
Accepted January 21, 2021